Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

HydrogenH2 Jul. 7 at 2:26 PM

$JNJ When Cramer say Buy @ 5 years high.... You...Well you know !! https://www.cnbc.com/2026/07/06/jim-cramer-stocks-buy-during-market-rotation.html

0 · Reply

JFDI Jul. 7 at 2:24 PM

$JNJ what a monster move

0 · Reply

StockBraker Jul. 7 at 2:15 PM

$JNJ New 52 week high.

0 · Reply

HydrogenH2 Jul. 7 at 1:59 PM

$JNJ $ABBV I'm taking 50% profits on both !! Thanks USA !!

0 · Reply

BarkingPuppy Jul. 7 at 1:56 PM

$ELTP $PFE $JNJ $MRNA $GME

0 · Reply

biolover Jul. 7 at 1:49 PM

$LLY $VKTX on the hands of $ABBV I beleive partnership is happening soon. This dyslocatuon in obesity market can’t continue forever. Not all managments as blind as $MRK and $JNJ

0 · Reply

MarketCommanderr Jul. 7 at 1:23 PM

Rep. Lloyd Doggett, Ranking Member of the Health Subcommittee, just reported buying up to $15K of $JNJ. That’s a stock directly tied to the pharma/med device space he helps legislate, so the optics are hard to ignore. $JNJ remains a name with clear policy sensitivity.

0 · Reply

TeresaTrades Jul. 7 at 1:21 PM

Largest PUT OI Decreases $JNJ $CIFR $ASTS $WULF $LCID

1 · Reply

The_Handoff_Crew Jul. 7 at 1:08 PM

$MNKD $JNJ $PFE $MRK Our crew believes Furoscix will be what saves this company.

1 · Reply

BarkingPuppy Jul. 7 at 1:03 PM

$ELTP $GME $JNJ $BAC Once SequestOx is approved we will be at 5.00 dollars and Up-listed. Its all about the SequestOx.

0 · Reply

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

2026-07-06T14:25:32.000Z - 1 day ago

Johnson & Johnson price target raised to $290 from $280 at HSBC

Jun 26, 2026, 2:39 PM EDT - 10 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

2026-06-26T16:40:11.000Z - 10 days ago

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

Jun 26, 2026, 12:35 PM EDT - 10 days ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

2026-06-26T12:36:03.000Z - 11 days ago

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

2026-06-25T09:10:22.000Z - 12 days ago

Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe

Jun 25, 2026, 5:00 AM EDT - 12 days ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

2026-06-16T20:26:11.000Z - 20 days ago

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

AMCR LOW

2026-06-15T11:17:46.000Z - 22 days ago

Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push

2026-06-15T10:05:07.000Z - 22 days ago

Johnson & Johnson invests more than $1B in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 22 days ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 24 days ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 24 days ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

2026-06-11T11:50:10.000Z - 26 days ago

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

Jun 11, 2026, 7:45 AM EDT - 26 days ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:14 AM EDT - 26 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

Jun 11, 2026, 2:03 AM EDT - 26 days ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 26 days ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 27 days ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 4 weeks ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 4 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 4 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 8:08 AM EDT - 4 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 5, 2026, 6:24 PM EDT - 4 weeks ago

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 3, 2026, 12:04 AM EDT - 4 weeks ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Jun 3, 2026, 12:03 AM EDT - 4 weeks ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 2, 2026, 6:24 PM EDT - 4 weeks ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

May 31, 2026, 8:39 AM EDT - 5 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:29 AM EDT - 5 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:27 AM EDT - 5 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:01 AM EDT - 5 weeks ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 29, 2026, 2:00 PM EDT - 5 weeks ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 8:18 AM EDT - 5 weeks ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 28, 2026, 7:10 PM EDT - 5 weeks ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 5:30 AM EDT - 5 weeks ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 27, 2026, 4:22 PM EDT - 5 weeks ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 11:00 AM EDT - 5 weeks ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 21, 2026, 7:00 AM EDT - 6 weeks ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 4:31 AM EDT - 6 weeks ago

Johnson & Johnson says nipocalimab approved in China

May 19, 2026, 11:30 AM EDT - 6 weeks ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:00 AM EDT - 7 weeks ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 14, 2026, 4:01 PM EDT - 7 weeks ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

May 12, 2026, 2:20 PM EDT - 7 weeks ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 11, 2026, 4:34 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 7, 2026, 11:34 AM EDT - 2 months ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 5, 2026, 9:15 AM EDT - 2 months ago

CVS to drop J&J's Stelara from its main formularies

CVS

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 7:00 AM EDT - 2 months ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 4, 2026, 8:00 AM EDT - 2 months ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 2, 2026, 4:00 AM EDT - 2 months ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Apr 30, 2026, 8:02 AM EDT - 2 months ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 28, 2026, 11:10 AM EDT - 2 months ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Apr 27, 2026, 4:33 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 11:03 AM EDT - 2 months ago

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 8:03 AM EDT - 2 months ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 24, 2026, 4:30 PM EDT - 2 months ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

HydrogenH2 Jul. 7 at 2:26 PM

$JNJ When Cramer say Buy @ 5 years high.... You...Well you know !! https://www.cnbc.com/2026/07/06/jim-cramer-stocks-buy-during-market-rotation.html

0 · Reply

JFDI Jul. 7 at 2:24 PM

$JNJ what a monster move

0 · Reply

StockBraker Jul. 7 at 2:15 PM

$JNJ New 52 week high.

0 · Reply

HydrogenH2 Jul. 7 at 1:59 PM

$JNJ $ABBV I'm taking 50% profits on both !! Thanks USA !!

0 · Reply

BarkingPuppy Jul. 7 at 1:56 PM

$ELTP $PFE $JNJ $MRNA $GME

0 · Reply

biolover Jul. 7 at 1:49 PM

$LLY $VKTX on the hands of $ABBV I beleive partnership is happening soon. This dyslocatuon in obesity market can’t continue forever. Not all managments as blind as $MRK and $JNJ

0 · Reply

MarketCommanderr Jul. 7 at 1:23 PM

0 · Reply

TeresaTrades Jul. 7 at 1:21 PM

Largest PUT OI Decreases $JNJ $CIFR $ASTS $WULF $LCID

1 · Reply

The_Handoff_Crew Jul. 7 at 1:08 PM

$MNKD $JNJ $PFE $MRK Our crew believes Furoscix will be what saves this company.

1 · Reply

BarkingPuppy Jul. 7 at 1:03 PM

$ELTP $GME $JNJ $BAC Once SequestOx is approved we will be at 5.00 dollars and Up-listed. Its all about the SequestOx.

0 · Reply

BarkingPuppy Jul. 7 at 12:51 PM

$ELTP $PFE $JNJ $MRNA ELTP’s financial fundamentals are surging with record breaking growth, but the stock price itself is experiencing a short term disconnect and has actually slipped. Elite Pharmaceuticals reported explosive, record-breaking results for its fiscal year 2026, driven by a massive expansion of its generic drug pipeline. NASRAT IS MAKING DEALS, LIKE NO ONE HAS EVER SEEN BEFORE.... MORE TO COME. Elite Pharma is the next best Meme Stock of 2026 and 2027

0 · Reply

grampslol Jul. 7 at 11:19 AM

Poor desperate $MNKD pumper @clan ... lol ... deluding himself as he tries to deceive the naive about furoscix and pennyworld Afizzle company... a sad 🤡 $JNJ $PFE $MRK

0 · Reply

Quantumup Jul. 7 at 11:16 AM

Truist⬆️ $PTGX's PT to $145 and said ~~ We reiterate our Buy rating of PTGX as we continue to be bullish on broader Icotyde commercial opportunity. $JNJ TAK $ABBV ALMS BMY ABVX Truist added—Johnson & Johnson (JNJ, NR) commentary on Icotyde continues to indicate 1) rapid access and uptake for the drug in Psoriasis; 2) strong KOL enthusiasm driven by label strength, & 3) comments around Ico potential to be "one of their biggest products ever", raising overall peak sales estimates beyond $10B. We have updated our model to reflect slightly increased market share of Icotyde in PsO; new PT is $145/sh vs. $121 prev. Additionally, we provide our perspective on PN-881 with focus on Ph2 start YE26.

0 · Reply

clan Jul. 7 at 10:24 AM

$MNKD $JNJ $PFE $MRK Billions ... in the U.S. alone. 🤑

0 · Reply

ElliottwaveForecast Jul. 7 at 10:22 AM

$JNJ is approaching towards 271.37 as initial target against 6.22.2026 low It is bullish in daily and expect continuation between 271.37 - 305.2 area to extend May-2026 rally. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ

0 · Reply

viggizags Jul. 7 at 6:29 AM

$SPY right now the saying is boring is exciting insurance killing it, banks killing it, character changes in a stock like $KMB one of the better performers this year is Woody Johnson coin $JNJ even better going out YoY. Had a joker laughing at me because i was posting about $C again boring is exciting. Tons of opportunity out there, even if the index turns down plenty if long opportunities.

0 · Reply

DidYouReadThis Jul. 7 at 5:55 AM

#DoYouWantToBuildASnowman? $DIS or try to #SetACommentRecord? $TSLA $AMC $JNJ $NAK . On original post please <3

0 · Reply

parcha Jul. 7 at 12:40 AM

Jim Cramer says these are the 5 stocks to buy during this market rotation $JNJ $PEP $SBUX $TJX CNBC’s Jim Cramer said investors should use the latest market rotation as an opportunity to buy high-quality companies that were swept lower by broad institutional selling. He highlighted Johnson & Johnson, PepsiCo, Starbucks, Constellation Brands and TJX as stocks that he thinks were unfairly caught up in the move. https://www.cnbc.com/2026/07/06/jim-cramer-stocks-buy-during-market-rotation.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension

1 · Reply

TroyTiger Jul. 7 at 12:22 AM

$TGTX $JNJ is an obvious buyout partner here. MW get this done...

1 · Reply

ElliottwaveForecast Jul. 7 at 12:14 AM

Do you actually know what confirms continuation in $JNJ before price breaks out? The bullish sequence remains active, pointing toward 271.37 and higher levels. Check out this 👉 https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #JNJ #trading #forecasting

0 · Reply

clan Jul. 6 at 8:23 PM

$ELTP With 2 upcoming cash-generating profitable quarters to be reported [early Aug and Nov], Elite stock will get up to > $1/sh by yr. end, just on operational output alone. Yes, a triple from here to 12/31/26. 💊💵 #drugmoney Take a look-see 👀 $TEVA $JNJ #pillpopper

1 · Reply

TraderDaKing Jul. 6 at 7:31 PM

$GME $JNJ $WEN

0 · Reply

Market Cap	633.19B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	23.67
Forward PE	22.74
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	6,803,700
Avg Vol	8,154,996
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	87%
Beta	0.24
Analysts	Strong Sell
Price Target	$260.04